Advertisement

Search Results

Advertisement



Your search for all items matches 226 pages

Showing 201 - 226


multiple myeloma

Lenalidomide, Bortezomib, and Dexamethasone Induction and Consolidation Effective in Multiple Myeloma in French Phase II Trial

In a phase II Intergroupe Francophone du Myélome (IFM) trial reported in the Journal of Clinical Oncology by Roussel et al, induction and consolidation treatment with RVD (lenalidomide [Revlimid], bortezomib [Velcade], and dexamethasone) followed by lenalidomide maintenance was associated...

multiple myeloma

High-Dose Melphalan Plus Autologous Stem Cell Transplantation as Consolidation Shows Benefit in Relapsed Multiple Myeloma After Previous Transplant

In a UK phase III trial (NCRI Myeloma X Relapse [Intensive] Trial) reported in The Lancet Oncology, Cook et al found that high-dose melphalan plus salvage autologous stem cell transplantation significantly prolonged time to progression vs cyclophosphamide in patients with relapsed multiple myeloma...

multiple myeloma
sarcoma

Scientists Engineer Nanoparticles to Prevent Bone Cancer, Strengthen Bones

A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent...

multiple myeloma

Combined Index Predicts Early Multiple Myeloma Progression-Related Death in Patients Receiving Front-Line Autologous Stem Cell Transplantation

In a European study reported in the Journal of Clinical Oncology, Moreau et al developed and validated a combined index for prognosis in patients with multiple myeloma treated with front-line autologous stem cell transplantation. The index, consisting of high lactate dehydrogenase (LDH) level,...

multiple myeloma

Immunotherapy May Be Effective in the Treatment of Multiple Myeloma

A new study by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma. The findings by ...

multiple myeloma

African Americans Have Higher Prevalence of Multiple Myeloma Precursor Than Whites and Hispanics

A large population-based study by Landgren et al has found that African Americans are more likely to have a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS), a precursor to the development of multiple myeloma, compared with whites or Hispanics. The study is published...

multiple myeloma

Lenalidomide, Particularly When Combined With Oral Melphalan, Increases Risk of Second Primary Hematologic Malignancy in Myeloma Therapy

Lenalidomide (Revlimid) has been associated with risk for second primary malignancies in patients with myeloma. In a meta-analysis of individual patient data reported in The Lancet Oncology, Palumbo et al found that lenalidomide was associated with a significantly increased risk of second primary...

multiple myeloma

Improved Survival With Four-Drug Induction Regimen Followed by Maintenance in Initial Treatment of Transplant-Ineligible Multiple Myeloma

In an updated analysis of an Italian phase III trial reported in the Journal of Clinical Oncology, Palumbo et al found that induction with bortezomib (Velcade), melphalan, prednisone, and thalidomide (Thalomid) followed by bortezomib plus thalidomide maintenance (VMPT-VT) significantly improved...

multiple myeloma
issues in oncology

Multiple Myeloma Study Shows Widespread Genetic Heterogeneity

A detailed study of tissue samples from more than 200 patients with multiple myeloma has found that an individual patient’s tumor can harbor populations of cancer cells equipped with different mutations. The result could have therapeutic ramifications for future patients, according to study...

multiple myeloma

Updated Myeloma Trial Shows Lenalidomide Maintenance Post-Transplant Improves Progression-Free But Not Overall Survival

A new analysis of the multiple myeloma IFM 2005-02 trial showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival. This is possibly attributed to the shorter survival time after first disease...

multiple myeloma

Continuous Lenalidomide/Low-Dose Dexamethasone Improves Survival vs Standard Treatment in Older Patients With Newly Diagnosed Myeloma

First-line treatment of newly diagnosed multiple myeloma using continuous treatment with the doublet of lenalidomide (Revlimid) and low-dose dexamethasone was superior to standard triplet treatment with melphalan, prednisone, and thalidomide (Thalomid) for 72 weeks, according to initial results of...

multiple myeloma

Three-Drug Regimen Produces High Response Rate in Relapsed/Refractory Multiple Myeloma

A phase II trial to evaluate the combination of bendamustine (Treanda) with bortezomib (Velcade) and dexamethasone in patients with relapsed/refractory multiple myeloma “showed a remarkable response rate of 60.9%, and, when minor responses were included in 75.9% of patients,”...

multiple myeloma

Multiple Myeloma Defined by Light Chain Amyloidosis With Plasma Cell or CRAB Criteria

In a study reported in Journal of Clinical Oncology, Taxiarchis V. Kourelis, MD, and colleagues from the Mayo Clinic attempted to define a threshold of bone marrow plasma cell number that could serve to define light chain amyloidosis as light chain amyloidosis with multiple myeloma. They found that ...

multiple myeloma

Addition of Vorinostat to Bortezomib Results in Small Progression-Free Survival Advantage in Previously-Treated Multiple Myeloma

In a phase III study (VANTAGE 088 trial) reported in The Lancet Oncology, Meletios Dimopolous, MD, of the University of Athens, and colleagues assessed the addition of the oral HDAC inhibitor vorinostat (Zolinza) to bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma. The...

multiple myeloma

Myeloma Foundation Launches Open Access Gateways to Accelerate Drug Development

The Multiple Myeloma Research Foundation (MMRF) has announced two open access gateways, the MMRF Researcher Gateway, which will upload genomic data as it becomes available and make it accessible to all researchers, and the MMRF CoMMunity Gateway, which will aggregate subtypes of myeloma patients...

multiple myeloma

Pomalidomide Produces ‘Impressive Results’ in Patients With Multiple Myeloma Who Are Refractory to Bortezomib and Lenalidomide

The second-generation immunomodulatory drug pomalidomide (Pomalyst) “has shown impressive results in patients with multiple myeloma who are refractory to lenalidomide and bortezomib,” according to a review of clinical data leading to the drug’s approval by the U.S. Food and Drug...

multiple myeloma

Researchers Uncover Root Cause of Multiple Myeloma Relapse

Researchers have discovered why multiple myeloma frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. The study, published in Cancer Cell, was a collaboration between researchers at Princess Margaret Hospital in Toronto, Mayo Clinic in...

multiple myeloma

Pomalidomide Plus Low-Dose Dexamethasone Improves Survival vs High-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma

Pomalidomide (Pomalyst) alone has shown limited efficacy in relapsed multiple myeloma, but synergistic effects have been noted when it is combined with dexamethasone. In a phase III trial (MM-003) reported in The Lancet Oncology, Jesus San Miguel, MD, of Universidad de Salamanca, and colleagues...

multiple myeloma

Panobinostat Combined With Bortezomib and Dexamethasone Can Recapture Responses in Heavily Pretreated Patients With Multiple Myeloma

The combination of the investigational histone deacetylase inhibitor panobinostat (Faridak) with bortezomib (Velcade) and dexamethasone was able to recapture responses in 34.5% of heavily pretreated, bortezomib-refractory patients with multiple myeloma in the phase II PANORAMA 2 trial. The 55...

multiple myeloma
issues in oncology

Gene That Helps Control Aging Is Linked to Multiple Myeloma

A telomerase RNA component gene called TERC, which is responsible for regulating the length of caps on the ends of DNA molecules and believed to be involved in the aging process, has been linked to the development of multiple myeloma, according to a study published in Nature Genetics. Researchers...

multiple myeloma

Lenalidomide plus Dexamethasone Delays Progression and Improves Survival in High-risk Smoldering Multiple Myeloma

In a study reported in The New England Journal of Medicine, María-Victoria Mateos, MD, PhD, of the Universidad de Salamanca, and colleagues compared induction lenalidomide (Revlimid) plus dexamethasone followed by maintenance lenalidomide with observation in patients with high-risk...

multiple myeloma
supportive care

New Guidelines Issued in the Treatment of Multiple Myeloma–related Bone Disease

The International Myeloma Working Group (IMWG) has developed clinical practice recommendations for the management of multiple myeloma–related bone disease based on published study data through August 2012. Consensus of the interdisciplinary panel of clinical experts on the plasma-cell...

multiple myeloma

Deep Sequencing Accurately Predicts Prolonged Survival in Multiple Myeloma Patients

A study by the Spanish Myeloma Group comparing the prognostic value of traditional response criteria and minimal residual disease measurement in patients with multiple myeloma found that a sequencing-based method called LymphoSIGHT and multiparameter flow cytometry analysis both accurately...

lymphoma
multiple myeloma

Breaking News on Lymphoma and Myeloma to Be Reported at European Hematology Congress in Stockholm

In order to support high-quality science, the European Hematology Association collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research. In simultaneous sessions on Thursday, June 13, during the European...

multiple myeloma

Daratumumab Receives Breakthrough Therapy Designation in Multiple Myeloma

FDA has granted daratumumab breakthrough therapy designation for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or who are double refractory to a proteasome inhibitor and...

multiple myeloma

FDA Approves Pomalidomide for Advanced Multiple Myeloma

The FDA approved pomalidomide (Pomalyst) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Pomalidomide, an oral immunomodulatory agent, is intended for patients who have received at least two prior therapies, including lenalidomide...

Advertisement

Advertisement



Advertisement